EP4045501A1 - Verfahren zur herstellung von 2-cyanoethyl (4s)-4-(4-cyano-2-methoxy-phenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxylat durch racemat-spaltung mittels diastereomerer weinsäureester - Google Patents
Verfahren zur herstellung von 2-cyanoethyl (4s)-4-(4-cyano-2-methoxy-phenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxylat durch racemat-spaltung mittels diastereomerer weinsäureesterInfo
- Publication number
- EP4045501A1 EP4045501A1 EP20789971.7A EP20789971A EP4045501A1 EP 4045501 A1 EP4045501 A1 EP 4045501A1 EP 20789971 A EP20789971 A EP 20789971A EP 4045501 A1 EP4045501 A1 EP 4045501A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- formula
- water
- stands
- cyano
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003899 tartaric acid esters Chemical class 0.000 title claims abstract description 57
- 238000000034 method Methods 0.000 title claims description 147
- 238000002360 preparation method Methods 0.000 title claims description 72
- AZFZQYUDLXNVMW-HXUWFJFHSA-N C(#N)C1=CC(=C(C=C1)[C@@H]1C(=C(NC2=C(C=NC(=C12)OCC)C)C)C(=O)OCCC#N)OC Chemical compound C(#N)C1=CC(=C(C=C1)[C@@H]1C(=C(NC2=C(C=NC(=C12)OCC)C)C)C(=O)OCCC#N)OC AZFZQYUDLXNVMW-HXUWFJFHSA-N 0.000 title claims description 30
- 150000003839 salts Chemical class 0.000 claims abstract description 130
- 150000001875 compounds Chemical class 0.000 claims abstract description 67
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 148
- 239000000203 mixture Substances 0.000 claims description 115
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 77
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 66
- -1 cyanoethanol ester Chemical class 0.000 claims description 54
- 239000002904 solvent Substances 0.000 claims description 44
- 239000000243 solution Substances 0.000 claims description 37
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 28
- 125000001072 heteroaryl group Chemical group 0.000 claims description 27
- 239000011877 solvent mixture Substances 0.000 claims description 24
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 22
- 239000001488 sodium phosphate Substances 0.000 claims description 22
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 22
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 22
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 claims description 20
- 235000011121 sodium hydroxide Nutrition 0.000 claims description 20
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 15
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims description 15
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 14
- 229910000160 potassium phosphate Inorganic materials 0.000 claims description 14
- 235000011009 potassium phosphates Nutrition 0.000 claims description 14
- 125000003107 substituted aryl group Chemical group 0.000 claims description 14
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 12
- 150000007529 inorganic bases Chemical class 0.000 claims description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 11
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 claims description 10
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 10
- 239000001099 ammonium carbonate Substances 0.000 claims description 10
- 235000013532 brandy Nutrition 0.000 claims description 10
- 150000007530 organic bases Chemical class 0.000 claims description 10
- 238000010992 reflux Methods 0.000 claims description 9
- 235000011008 sodium phosphates Nutrition 0.000 claims description 9
- 230000003197 catalytic effect Effects 0.000 claims description 8
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 claims description 7
- 235000011118 potassium hydroxide Nutrition 0.000 claims description 7
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 7
- 235000017550 sodium carbonate Nutrition 0.000 claims description 7
- 239000004254 Ammonium phosphate Substances 0.000 claims description 6
- 229910000148 ammonium phosphate Inorganic materials 0.000 claims description 6
- 235000019289 ammonium phosphates Nutrition 0.000 claims description 6
- NSFIAKFOCAEBER-QZTJIDSGSA-N (2s,3s)-2,3-dihydroxy-2,3-bis(4-methylphenyl)butanedioic acid Chemical compound C1=CC(C)=CC=C1[C@@](O)(C(O)=O)[C@](O)(C(O)=O)C1=CC=C(C)C=C1 NSFIAKFOCAEBER-QZTJIDSGSA-N 0.000 claims description 5
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 claims description 5
- 229910021529 ammonia Inorganic materials 0.000 claims description 5
- 235000012538 ammonium bicarbonate Nutrition 0.000 claims description 5
- 235000012501 ammonium carbonate Nutrition 0.000 claims description 5
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 claims description 5
- 229910052808 lithium carbonate Inorganic materials 0.000 claims description 5
- 239000011736 potassium bicarbonate Substances 0.000 claims description 5
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 5
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 5
- 235000011181 potassium carbonates Nutrition 0.000 claims description 5
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 5
- 229940086066 potassium hydrogencarbonate Drugs 0.000 claims description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 5
- 238000007127 saponification reaction Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 185
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 42
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 37
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 33
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 27
- 239000000047 product Substances 0.000 description 26
- BTBHLEZXCOBLCY-QGZVFWFLSA-N (4s)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide Chemical compound C1([C@@H]2C(=C(C)NC=3C(C)=CN=C(C2=3)OCC)C(N)=O)=CC=C(C#N)C=C1OC BTBHLEZXCOBLCY-QGZVFWFLSA-N 0.000 description 25
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 21
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 21
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 20
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 18
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 18
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 18
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 16
- 230000015572 biosynthetic process Effects 0.000 description 15
- 239000000843 powder Substances 0.000 description 15
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 14
- 229950004408 finerenone Drugs 0.000 description 13
- 239000003960 organic solvent Substances 0.000 description 12
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 11
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 10
- 239000013078 crystal Substances 0.000 description 10
- 238000002156 mixing Methods 0.000 description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 10
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 8
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical class N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 8
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical class C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 8
- 238000011109 contamination Methods 0.000 description 8
- 238000001914 filtration Methods 0.000 description 8
- 238000002955 isolation Methods 0.000 description 8
- NTOIKDYVJIWVSU-WOJBJXKFSA-N (2r,3r)-2,3-dihydroxy-2,3-bis(4-methylbenzoyl)butanedioic acid Chemical compound C1=CC(C)=CC=C1C(=O)[C@@](O)(C(O)=O)[C@](O)(C(O)=O)C(=O)C1=CC=C(C)C=C1 NTOIKDYVJIWVSU-WOJBJXKFSA-N 0.000 description 7
- 238000005160 1H NMR spectroscopy Methods 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 239000012535 impurity Substances 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 6
- 125000003118 aryl group Chemical group 0.000 description 6
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 6
- 229910052801 chlorine Inorganic materials 0.000 description 6
- 239000000460 chlorine Substances 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 229910052731 fluorine Inorganic materials 0.000 description 6
- 239000011737 fluorine Substances 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 6
- WOFDVDFSGLBFAC-UHFFFAOYSA-N lactonitrile Chemical compound CC(O)C#N WOFDVDFSGLBFAC-UHFFFAOYSA-N 0.000 description 6
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 5
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 5
- 125000003368 amide group Chemical group 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- 229910052794 bromium Inorganic materials 0.000 description 5
- 125000004093 cyano group Chemical group *C#N 0.000 description 5
- 150000003950 cyclic amides Chemical class 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 229910052740 iodine Inorganic materials 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- QLAPRUDHLUJVMG-IBGZPJMESA-N CCOC1=C([C@@H](C=C(C)N2CCC#N)C(C=CC(C#N)=C3)=C3OC)C2=C(C)C=N1 Chemical compound CCOC1=C([C@@H](C=C(C)N2CCC#N)C(C=CC(C#N)=C3)=C3OC)C2=C(C)C=N1 QLAPRUDHLUJVMG-IBGZPJMESA-N 0.000 description 4
- CTEQWCKBTWAWIH-QGZVFWFLSA-N CCOC1=NC=C(C2=C1[C@@H](C(=C(N2)C)C(=O)O)C3=C(C=C(C=C3)C#N)OC)C Chemical compound CCOC1=NC=C(C2=C1[C@@H](C(=C(N2)C)C(=O)O)C3=C(C=C(C=C3)C#N)OC)C CTEQWCKBTWAWIH-QGZVFWFLSA-N 0.000 description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 4
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 4
- 125000001033 ether group Chemical group 0.000 description 4
- 125000005843 halogen group Chemical group 0.000 description 4
- 239000011630 iodine Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 150000004950 naphthalene Chemical class 0.000 description 4
- UFWIBTONFRDIAS-UHFFFAOYSA-N naphthalene-acid Natural products C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 3
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 3
- 235000019445 benzyl alcohol Nutrition 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 238000005580 one pot reaction Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 125000003373 pyrazinyl group Chemical group 0.000 description 3
- 125000003226 pyrazolyl group Chemical group 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- 125000000168 pyrrolyl group Chemical group 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229930192474 thiophene Natural products 0.000 description 3
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 2
- 125000006164 6-membered heteroaryl group Chemical group 0.000 description 2
- JHWIWZLGTMIMFG-UHFFFAOYSA-N CCOC1=NC=C(C2=C1CC(=C(N2)C)C(=O)O)C Chemical compound CCOC1=NC=C(C2=C1CC(=C(N2)C)C(=O)O)C JHWIWZLGTMIMFG-UHFFFAOYSA-N 0.000 description 2
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 239000003398 denaturant Substances 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 125000001715 oxadiazolyl group Chemical group 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 2
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 2
- 239000012088 reference solution Substances 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 235000015096 spirit Nutrition 0.000 description 2
- 229960001367 tartaric acid Drugs 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 125000004306 triazinyl group Chemical group 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- YNIRKEZIDLCCMC-UHFFFAOYSA-K trisodium;phosphate;hydrate Chemical compound [OH-].[Na+].[Na+].[Na+].OP([O-])([O-])=O YNIRKEZIDLCCMC-UHFFFAOYSA-K 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- ACMSDYGOIVWQIX-CQSZACIVSA-N (2r)-n-(dicyclopropylmethyl)-4-methyl-2-(2-methylprop-2-enoylamino)pentanamide Chemical compound C1CC1C(NC(=O)[C@H](NC(=O)C(C)=C)CC(C)C)C1CC1 ACMSDYGOIVWQIX-CQSZACIVSA-N 0.000 description 1
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 1
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 1
- 125000006218 1-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- AZFZQYUDLXNVMW-UHFFFAOYSA-N 2-cyanoethyl 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxylate Chemical compound C1=2C(OCC)=NC=C(C)C=2NC(C)=C(C(=O)OCCC#N)C1C1=CC=C(C#N)C=C1OC AZFZQYUDLXNVMW-UHFFFAOYSA-N 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- CTEQWCKBTWAWIH-UHFFFAOYSA-N 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxylic acid Chemical compound C1=2C(OCC)=NC=C(C)C=2NC(C)=C(C(O)=O)C1C1=CC=C(C#N)C=C1OC CTEQWCKBTWAWIH-UHFFFAOYSA-N 0.000 description 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- QJFWCYSYIGGWMP-YUMQZZPRSA-N O[C@@H]([C@@H](C(OC(C(C=C1)=CC=C1Cl)=O)=O)O)C(O)=O Chemical compound O[C@@H]([C@@H](C(OC(C(C=C1)=CC=C1Cl)=O)=O)O)C(O)=O QJFWCYSYIGGWMP-YUMQZZPRSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- LFVGISIMTYGQHF-UHFFFAOYSA-N ammonium dihydrogen phosphate Chemical compound [NH4+].OP(O)([O-])=O LFVGISIMTYGQHF-UHFFFAOYSA-N 0.000 description 1
- 229910000387 ammonium dihydrogen phosphate Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000003889 chemical engineering Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- GEAXLHPORCRESC-UHFFFAOYSA-N chlorocyclohexatriene Chemical compound ClC1=CC=C=C[CH]1 GEAXLHPORCRESC-UHFFFAOYSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000011157 data evaluation Methods 0.000 description 1
- 229940075894 denatured ethanol Drugs 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- ORYOIBJWFDNIPD-PHDIDXHHSA-N diacetyl (2r,3r)-2,3-dihydroxybutanedioate Chemical compound CC(=O)OC(=O)[C@H](O)[C@@H](O)C(=O)OC(C)=O ORYOIBJWFDNIPD-PHDIDXHHSA-N 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- JXBPSENIJJPTCI-UHFFFAOYSA-N ethyl cyanate Chemical compound CCOC#N JXBPSENIJJPTCI-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000011552 falling film Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- JBFYUZGYRGXSFL-UHFFFAOYSA-N imidazolide Chemical compound C1=C[N-]C=N1 JBFYUZGYRGXSFL-UHFFFAOYSA-N 0.000 description 1
- 238000011078 in-house production Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002395 mineralocorticoid Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 235000019837 monoammonium phosphate Nutrition 0.000 description 1
- 125000001298 n-hexoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 description 1
- 229940072033 potash Drugs 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- FVEFRICMTUKAML-UHFFFAOYSA-M sodium tetradecyl sulfate Chemical compound [Na+].CCCCC(CC)CCC(CC(C)C)OS([O-])(=O)=O FVEFRICMTUKAML-UHFFFAOYSA-M 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000008030 superplasticizer Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B57/00—Separation of optically-active compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C68/00—Preparation of esters of carbonic or haloformic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
- C07C69/675—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids of saturated hydroxy-carboxylic acids
- C07C69/70—Tartaric acid esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
- C07C69/78—Benzoic acid esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Definitions
- the present invention relates to the diastereomeric salts (Va), (Vb), (Vc) and / or (Vd), a process for the preparation of the diastereomeric salts (Va), (Vb), ( Vc) and / or (Vd) using a chiral substituted tartaric acid ester of the formula (IIIa) or (IIIb), a process for the preparation of the compound according to formula (IVa) using the diastereomer salts (Va), (Vb), ( Vc) and / or (Vd), a process for the preparation of the compound according to formula (VIIa) using the diastereomer salt
- the above-mentioned compounds are intermediates or precursors in the synthesis of finerenones (formula (Ia)).
- the term "Finerenone” refers to the compound (4S) -4- (4-cyano-2-methoxyphenyl) -5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3- carbox-amide or the compound according to formula (Ia) .
- antipodes of Finerenone or “antipodes of the compound according to formula (I)” refers to the compounds according to formula (Ia) and (Ib)
- Finerenone (Ia) acts as a non-steroidal antagonist of the mineral corticoid receptor and can be used as an agent for the prophylaxis and / or treatment of cardiovascular and renal diseases such as heart failure and diabetic nephropathy.
- the SMB separation delivers a very good yield and optical purity
- the acquisition costs and operation of such a system under GMP conditions are a great challenge and are associated with high costs.
- the chiral phase used in each case is also very expensive and only has a limited lifespan and has to be replaced again and again in ongoing production. For technical production reasons, this is not optimal if a second system is not available so that continuous operation is guaranteed, which is associated with additional costs.
- the recovery of the solvent is the time-determining step and requires the purchase of huge falling film evaporators and is associated with the consumption of enormous amounts of energy.
- the synthesis of the racemic cyanoethanol ester according to formula (IV) is described in WO 2016/016287 A1 (cf. Example 5, in WO 2016/016287 A1 this is the compound according to formula (XI)).
- Table 1 lists the acids used for the resolution. This was in various organic solvents, such as in pure alcohols (methanol, ethanol, 1-propanol, 2-propanol, butanol), as well as their mixtures with water, as well as THF, acetone, ethyl acetate, dichloromethane and a number of other solvents the racemate (IV) implemented and examined for diastereomer salt formation.
- alkyl-substituted tartaric acid derivatives such as, for example, (-) - O, O'-dipivaloyl-L-tartaric acid or (-) - O, O'-diacetyl-L-tartaric acid.
- aromatically or heteroaromatically substituted derivatives of tartaric acid (IIIa + IIIb) are excellently suited to obtain diastereomeric salts and to achieve the required enantiomeric excess.
- the invention relates to the following subjects:
- the new methods according to the invention can be used in many more cost-effective methods or plants in contrast to the prior art described above;
- the new methods according to the invention can be carried out with conventional pilot plant equipment (stirred tank / isolation apparatus) - such systems traditionally belong to the standard equipment of pharmaceutical production companies and do not require any additional investments.
- the new processes according to the invention can be carried out on an industrial scale
- the diastereomer salts obtained by the process according to the invention are distinguished by a high enantiomeric excess, generally> 95% e.e., which is sufficient to convert finerenones in>> 99% e.e. to manufacture.
- the diastereomer salts do not necessarily have to be dried, but can also be used moist in the next process stage. This means that one-pot processes are also possible;
- the present application therefore relates to a process for the preparation of 2-cyanoethyl (4S) -4- (4- cyano-2-methoxyphenyl) -5-ethoxy-2,8-dimethyl-1,4-dihydro-1, 6-naphthyridine-3-carboxylate of the formula (IVa) by resolution of the racemate (IV) , with a chiral substituted tartaric acid ester of the formula (IIIa), where Ar is unsubstituted or substituted aryl or heteroaryl.
- substituted means that one or more hydrogen atoms on the relevant atom or the relevant group is / are replaced by a selection from the specified group, with the proviso that the normal valence of the relevant atom is not exceeded under the present circumstances . Combinations of substituents and / or variables are allowed.
- unsubstituted means that no hydrogen atom has been replaced.
- the heteroaryl group can be a 5-membered heteroaryl group such as, for example, thienyl, furanyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl or tetrazolyl; or a 6-membered heteroaryl group such as, for example, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl or triazinyl; ora tricyclic heteroaryl group such as, for example, carbazolyl, acridinyl or phenazinyl; or a 9-membered heteroaryl group such as, for example, benzofuranyl, benzothienyl, benzoxazolyl, benzisoxazolyl, benzimidazolyl, benzothiazolyl
- the heteroaryl group is a pyridinyl, pyrazinyl, pyrrolyl, pyrazolyl or pyrimidinyl group.
- aryl group is in particular a phenyl group.
- Substituents for the purposes of the present invention are halogen, C 1 -C 6 -alkyl, C 1 -C- 6 alkoxy, nitrile, nitro, cyano, CF 3 , an amide group, such as -NHCOR, in which R is methyl, ethyl or phenyl, a -NRCOR group in which R has the meaning given above, a -CONHR group in which R has the meaning given above, a CONRR 'in which R can stand for methyl, ethyl or phenyl and R 'can represent methyl, ethyl or phenyl or cyclic amides such as 3-oxomorpholin-4-yl, 2-oxopiperidin-1-yl, which in turn can be substituted.
- amide group such as -NHCOR, in which R is methyl, ethyl or phenyl, a -NRCOR group in which R has the meaning given above,
- halogen denotes a fluorine, chlorine, bromine or iodine atom, in particular a fluorine, chlorine or bromine atom.
- C 1 -C 6 -alkyl means a straight-chain or branched saturated monovalent hydrocarbon group having 1, 2, 3, 4, 5 or 6 carbon atoms, for example a methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl, tert-butyl, pentyl, isopentyl, 2-methylbutyl, 1-methylbutyl, 1-ethylpropyl, 1,2-dimethylpropyl, neopentyl, 1,1-dimethylpropyl , Hexyl, 1-methylpentyl, 2- Methylpentyl, 3-methylpentyl, 4-methylpentyl, 1-ethylbutyl, 2-ethylbutyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl, 2,3-dimethylbutyl , 1,2-dimethylbutyl, or
- the group has in particular 1, 2, 3 or 4 carbon atoms (“C 1 -C 4 -alkyl”), for example methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl or tert-butyl group, in particular 1, 2 or 3 carbon atoms (“C 1 -C 3 -alkyl”), for example a methyl, ethyl, n-propyl or isopropyl group.
- C 1 -C 4 -alkyl for example methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl or tert-butyl group
- C 1 -C 3 -alkyl for example a methyl, ethyl, n-propyl or isopropyl group.
- C 1 -C 6 -alkoxy means a straight-chain or branched saturated monovalent group of the formula (C 1 -C 6 -alkyl) -O-, in which the term “C 1 -C 6 -alkyl” is defined as above is, for example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, isobutoxy, tert-butoxy, pentyloxy, isopentyloxy or n-hexyloxy group or an isomer thereof.
- Ar preferably stands for: where # stands for the point of attachment, where RI, R2, R3, R4, R5 each represent a hydrogen atom or an alkyl radical, such as, for example, methyl, ethyl, propyl or a halogen atom, such as, for example, fluorine, chlorine, bromine or iodine or an ether group , such as O-methyl, O-ethyl, O-phenyl, or a nitro group, or a cyano group, or a CF3 group, or an amide group, such as -NHCOR, in which R is methyl, ethyl or phenyl can, or - NRCOR in which R has the meaning given above or CONHR - in which R has the meaning given above or CONRR ', in which R can stand for methyl, ethyl or phenyl and R' can stand for methyl, ethyl or phenyl or for cyclic amides such as 3-ox
- substitution patterns can be very different, so theoretically up to 5 different substituents can be possible, but as a rule the monosubstituted Ar radicals are preferred.
- Ar can also be a substituted heteroaromatic, such as preferably pyridine or pyrazine.
- Ar can also be used for a political aromatic hydrocarbon, such as. for example a substituted naphthalene, anthracene, or quinoline.
- Ar is particularly preferably one of the formulas
- Ar is particularly preferably one of the formulas where * stands for the connection point.
- Ar radicals are: where * stands for the connection point.
- the p-toloyl radical and the 4-chlorophenyl radical are particularly preferred.
- the p-toloyl radical is particularly preferred.
- the production of tartaric acid esters is known from the literature, for example in Organic Synthesis, Coli. Vol. 9, p.722 (1998); Vol. 72, p.86 (1995), as well as in Chirality 2011 (23), 3, p.228.
- Another object of the invention relates to diastereomer salts (Va to Vd) according to the formulas
- Diastereomer salts in which Ar stands for p-toloyl are particularly preferred.
- the mirror-image salt of the general form (Vb) is prepared by combining the racemate (II) with the tartaric acid Reacts derivative of the general formula (IIIb), the antipode of the R configuration preferably entering into salt formation.
- the precipitated diastereomer salts can be separated off almost quantitatively, the S antipode remaining in solution here.
- Finerenone (I) has the S configuration. Both S, S-configured and R, R-configured tartaric acid esters (depending on the type of substitution) can form diastereomeric salts with the 4 S -configured enantiomer of racemate IV.
- 0.5 to 2.0 equivalents of tartaric acid ester (IIIa) or (IIIb) are used for the racemate resolution, but preferably 0.7 to 1.5 equivalents, particularly preferably 0.7 to 1.4 equivalents, very particularly preferably 0.70-1.2 equivalents.
- the diastereomer salt formation takes place in organic solvents or solvent mixtures which consist of water and water-miscible organic solvents.
- Suitable organic solvents for the purposes of the application are, for example, ethanol, methanol, isopropanol, 1-propanol, ethyl acetate, isobutanol, dichloromethane, 1-pentanol or acetone, but preference is given to using ethanol.
- the solvents can also be used in the commercially available denatured form, such as the denaturing agents used in ethanol, for example toluene, methyl ethyl ketone, thiophene, hexane, which for reasons of cost has great advantages and is therefore particularly suitable for large-scale use of brandy, which in the sense the application consists of ethanol which can optionally be denatured with toluene or methyl ethyl ketone. So when “brandy” is mentioned, denatured ethanol is meant. The term “brandy” is known to those skilled in the art.
- the ratio of volume to volume (vol / vol) is meant.
- a solvent mixture which for example consists of ethanol / water 80:20, contains 80 mL ethanol and 20 mL water. The volume thus relates to the total volume of the solvent.
- the mixture can be prepared beforehand, or else in situ, after all components have been presented in one pot.
- the solvent mixture can be used in a 10- to 60-fold excess based on the racemate (IV), ie 10L to 40L solvent mixture are used for 1 kg of racemate. A 10- to 50-fold excess is preferred.
- the racemate is usually resolved by first placing all of the components in the solvent mixture at room temperature, then heating to 10 ° C to 60 ° C, but preferably to 20 ° C - 50 ° C and 1 to 10 hours, preferably 1 to 4 hours at 20 ° C-50 ° C and then within 3 to 24 hours, preferably 5-16 hours, to room temperature (approx. 20 ° C-23 ° C). The mixture is then allowed to stir for 2 to 24 hours, preferably 5 to 18 hours, very preferably 12 to 16 hours at room temperature.
- the racemate resolution is preferably carried out at a temperature of 20 ° C - 50 ° C.
- Isolation is carried out by methods known to the person skilled in the art, such as, for example, by filtration or using a centrifuge.
- the filter cake obtained in this way can be rewashed once or several times with a solvent or solvent mixture. This is followed by drying under vacuum, preferably ⁇ 100 mbar at an elevated temperature (50-80 ° C., preferably 50 ° C.).
- the use of drag gas has proven to be advantageous in some cases.
- diastereomer salts with an enantiomeric excess of the diastereomer salts in the range from 65% to 80% e.e. to manufacture.
- the diastereomer salts do not necessarily have to be dried, but can also be used moist in the next process stage.
- Suitable organic solvents for the purposes of the application are, for example, ethanol, methanol, isopropanol, 1-propanol, ethyl acetate, isobutanol, dichloromethane, 1-pentanol or acetone, but preference is given to using ethanol.
- the solvents can also be used in the commercially available denatured form, such as the denaturants used in ethanol, for example toluene, methyl ethyl ketone, thiophene, hexane, which has great advantages for reasons of cost.
- spirits are particularly suitable for large-scale industrial use, which in the sense of the application consists of ethanol which can optionally be denatured with toluene or methyl ethyl ketone.
- solvents were also used: ethyl acetate / methanol 90:10; Methanol / water 80:20; Ethanol / water 90:10; Ethanol / water 85:15; Ethanol / water 80:20; Ethanol / water 75:25; Ethanol / water 70:30; Dichloromethane; 1-propanol / water 80:20; 1-pentanol; 1-pentanol / water 90:10; Isopropanol; Isopropanol / water 80:20; Isobutanol / water 90:10; Isobutanol / water 80:20; Cyclohexanol / water 90:10; Benzyl alcohol / water
- the mixture can be prepared beforehand, or it can be generated in situ after all components have been presented in a pot.
- the solvent mixture can be used in a 10- to 60-fold excess based on the racemate (IV), i.e. 10L to 40L solvent mixture are used for 1kg racemate. A 10- to 50-fold excess is preferred.
- the execution takes place by first introducing all components in the solvent mixture at room temperature, then heated to 10 ° C to 60 ° C, but preferably to 20 ° C - 50 ° C and 1 to 10 hours, preferably 1 to 4 hours at 20 ° C-50 ° C and then within 3 to 24 hours, preferably 5-16 hours, to room temperature (approx. 20 ° C-23 ° C).
- the mixture is then allowed to stir for 2 to 24 hours, preferably 5 to 18 hours, very preferably 12 to 16 hours at room temperature.
- the precipitated diastereomer salt (Va) or (Vb) or (Vc) and / or (Vd) is then isolated.
- Isolation is carried out by methods known to the person skilled in the art, such as, for example, by filtration or using a centrifuge.
- the filter cake obtained in this way can once or several times with a solvent or Solvent mixture can be washed down. This is followed by drying under vacuum, preferably ⁇ 100 mbar at an elevated temperature (50 ° C.-80 ° C., preferably 50 ° C.).
- the use of drag gas has proven to be advantageous in some cases.
- the diastereomer salts obtained in this way are distinguished by a high enantiomeric excess, generally> 95% ee, which is sufficient to produce finerenones in>> 99% ee.
- the diastereomer salts do not necessarily have to be dried, but can also be used moist in the next process stage.
- the diastereomer salt is treated with a base and the solvent is removed.
- the solvent is removed by methods known to the person skilled in the art, for example by distilling off.
- the diastereomer salt of the general formula (Va), (Vb), (Vc) or (Vd) must be treated with a base, the target molecule (IVa) or ( IVb) after the organic solvent has been distilled off from the solution, it is isolated - for example by filtering off and washing and the respective tartaric acid ester according to formula (IIIa) or (IIIb) remains in solution in salified form.
- Inorganic and organic bases are suitable as bases for the purposes of the present invention.
- inorganic bases ammonia, sodium hydroxide solution, lithium hydroxide, potassium hydroxide, ammonium carbonate, sodium carbonate, potassium carbonate, lithium carbonate, ammonium hydrogen carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate, sodium phosphate, potassium phosphate, ammonium phosphate can be used.
- Sodium phosphate or potassium phosphate is particularly preferably used.
- the inorganic bases can be used both in anhydrous form and in the form of their hydrates, for example sodium phosphate (anhydrous) and sodium phosphate hydrate can be used successfully.
- Aliphatic or aromatic bases such as, for example, triethylamine, imidazole, N-methylimidazole, Hunig base, pyridine, DBU, can be used as the organic base.
- the release of the target compound (IVa) or (IVb) takes place in mixtures of water, water-miscible organic solvents such as ethanol, isopropanol, 1,2-ethanediol, methoxyethanol, methanol or acetone, ethanol is preferred.
- the solvents can also be used in the commercially available denatured form, such as the denaturants used for ethanol, for example toluene, methyl ethyl ketone, thiophene, hexane; preference is given to brandy which, in the sense of the application, consists of ethanol, which can optionally be denatured with toluene or methyl ethyl ketone used, which has great advantages for reasons of cost.
- the mixture can be prepared beforehand, or it can be generated in situ after all components have been presented in a pot. 7 to 20 times this mixture based on the diastereomer salt used (IVa or IVb or IVc or IVd) can be used, for example 1 kg in 7 L to 20 L of this mixture. It is preferred to use 8 to 15 times this mixture, particularly preferably 9 to 11 times this mixture, which is very particularly preferred 10 times the mixture.
- the target compound (IVa) or (IVb) is released by initially introducing the diastereomer salt (Va or Vb or Vc or Vd) in a solvent mixture at 0 ° C to 60 ° C, preferably 0 ° C to 50 ° C, then adding it the organic or inorganic base (either in solid form or as a solution, preferably in water) has a pH of 6.9 to 8.0, preferably a pH of 7.0 to 7.5, particularly preferably pH 7 , 1 sets.
- Inorganic and organic bases are suitable as bases for the purposes of the present invention.
- inorganic bases ammonia, sodium hydroxide solution, lithium hydroxide, potassium hydroxide, ammonium carbonate, sodium carbonate, potassium carbonate, lithium carbonate, ammonium hydrogen carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate, sodium phosphate, potassium phosphate, ammonium phosphate can be used.
- Sodium phosphate or potassium phosphate is particularly preferably used. It is important to emphasize that the inorganic bases can be used both in anhydrous form and in the form of their hydrates, for example sodium phosphate (anhydrous) and sodium phosphate hydrate can be used successfully.
- Aliphatic or aromatic bases such as, for example, triethylamine, imidazole, N-methylimidazole, Hunig base, pyridine, DBU, can be used as the organic base.
- the base can optionally be added very quickly (within a few minutes) or very slowly (within several hours, for example in 5 minutes to 3 hours. A faster addition is preferred in any case. Is preferred within 5 minutes to A pH meter built into the reactor can be used for this, with which the setting is monitored and the base is slowly added. However, a fixed amount of base (solid or dissolved in a solvent) can also be added right from the start. which, based on empirical values, ensures that the desired pH value range is preferably reached. Such a procedure is most preferred in production. It has proven to be advantageous if, after the pH value has been set, the temperature is again set at 0 ° C -50 ° C., preferably 20 ° C.-50 ° C., preferably 0 ° C. -20 ° C. The subsequent stirring time can be 1 to 10 hours, preferably 2-5 hours, particularly preferably 3-4 hours.
- Isolation is carried out by methods known to the person skilled in the art, such as, for example, by filtration or using a centrifuge.
- the filter cake obtained in this way can be rewashed once or several times with a solvent or solvent mixture. This is followed by drying under vacuum, preferably ⁇ 100 mbar at an elevated temperature (50-80 ° C., preferably 50 ° C.).
- the use of drag gas has proven to be advantageous in some cases.
- a particularly preferred process, especially for large-scale implementation, is di-p-toloyl-D-tartaric acid (IIIa '), which can be used both in anhydrous form and as a hydrate:
- the resolution is preferably carried out in a mixture of spirits and water.
- the subsequent release of (IVa) preferably takes place in a brandy-water mixture using sodium phosphate as the base. It is also possible to isolate the target enantiomer from the mother liquor.
- the corresponding diastereomer salt (Va), (Vb), (Vc) or (Vd) of either (IVa) or (IVb) is first prepared, then isolated by filtration and then the pH of the mother liquor, which then the contains the respective antipodes, by adding a base such as ammonia, caustic soda, lithium hydroxide, potassium hydroxide, Ammonium carbonate, sodium carbonate, potassium carbonate, lithium carbonate, ammonium hydrogen carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate, sodium phosphate, potassium phosphate, ammonium phosphate, preferably sodium hydroxide, sodium phosphate and potassium phosphate, particularly preferably sodium phosphate and potassium phosphate, adjusted to pH> 7, pH 7.1-8 being preferred, pH
- the organic solvent - preferably ethanol - is then distilled off, either at normal pressure or more gently under reduced pressure.
- the corresponding antipode fails.
- the product is filtered off, washed with water or water / solvent mixtures and dried.
- a corresponding final crystallization from brandy, as described, for example, in Example 1c, provides the compounds (IVa) and (IVb) in appropriately pure form.
- reaction can very easily be carried out in a relatively concentrated manner in mixtures of THF / water.
- a mixture of THF / water 2: 1 (9-fold) is used, the sodium hydroxide solution is metered in at 0 ° C -5 ° C, then stirred at 0 ° C -5 ° C for 1-2 hours. Potash can also be used, but caustic soda is preferred.
- extraction is carried out with MTBE (methyl tert-butyl ether) and ethyl acetate or just toluene and, for isolation, the pH is adjusted to 7 with a mineral acid such as hydrochloric acid, sulfuric acid or phosphoric acid, but preferably hydrochloric acid.
- the resulting disilylamide compound can optionally be isolated. However, it has proven to be more advantageous to continue in a one-pot reaction. When the reaction has ended, the mixture is therefore cooled to 0 ° C.-3 ° C. and water or a mixture of water / THF is metered in. It has proven to be advantageous to use an amount of water of 0.5 to 0.7 times (based on the starting material), and an amount of 0.52 times of water is particularly advantageous.
- the water can be metered in directly or in a mixture with approximately one to twice the volume of THF.
- the mixture is refluxed for a total of 1-3 hours, preferably 1 hour.
- the mixture is cooled to 0 ° C. and stirred for 1-5 hours, preferably 3 hours, at this temperature.
- the product is then isolated by filtration or centrifugation. It is washed with THF and water and dried in vacuo at an elevated level
- the yields are very high and are> 93% of theory. Theory. The purity is> 99% (HPLC, 100% method).
- the compound (VIIa or VIIb) can also be obtained directly by reaction with ammonia gas in an autoclave (approx. 25 to 30 bar). To do this, the preactivation described above is carried out and then heated under pressure under ammonia gas. When the reaction has ended, the mixture is cooled and the product is filtered off. The yields and purities achieved in this way are comparable.
- the present invention therefore also relates to a process for the preparation of (4S) - 4- (4-cyano-2-methoxyphenyl) -5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3 -carbox-amide of the formula (Ia)
- the present invention relates to a process for the preparation of 2-cyanoethyl (4S) -4- (4-cyano-2-methoxyphenyl) -5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6- naphthyridine-3-carboxylate of the formula (IVa) by resolution of racemic 2-cyanoethyl (4S) -4- (4-cyano-2-methoxyphenyl) -5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxylate of formula (IV) with a chiral substituted tartaric acid ester of the formula (IIIa)
- substitution patterns can be very different, so theoretically up to 5 different substituents can be possible, but as a rule the monosubstituted Ar radicals are preferred.
- Ar can also be a substituted heteroaromatic, such as preferably pyridine or pyrazine.
- Ar can also be used for a political aromatic hydrocarbon, such as. for example a substituted naphthalene, anthracene, or quinoline.
- the present invention also relates to a process for the preparation of (4S) -4- (4-cyano-2-methoxyphenyl) -5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3- carbox-amide of formula (Ia) characterized in that one racemic cyanoethanol ester of the formula (IV) with a chiral substituted tartaric acid ester of the formula (IIIa) where Ar stands for unsubstituted or substituted aryl or heteroraryl, in enantiomeric cyanoethanol ester 2-cyanoethyl (4S) -4- (4-cyano-2-methoxyphenyl) -5-ethoxy-2,8-dimethyl-1,4-dihydro -1,6-naphthyridine-3-carboxylate of the formula (IVa) transferred, and this in a THF / water mixture (2: 1) with sodium
- a process for the preparation of (4S) -4- (4-cyano-2-methoxyphenyl) -5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide is preferred of formula (Ia) characterized in that one racemic cyanoethanol ester of the formula (IV) with a chiral substituted tartaric acid ester of the formula (IIIa) where Ar for where # stands for the point of attachment, where R1, R2, R3, R4, R5 each represent a hydrogen atom or an alkyl radical, such as methyl, ethyl, propyl or a halogen atom, such as fluorine, chlorine, bromine or iodine or an ether group, such as, for example, O-methyl, O-ethyl, O-phenyl, or a nitro group, or a cyano group, or a CF3 group, or an amide group, such as, for example, -NH
- substitution patterns can be very different, so theoretically up to 5 different substituents can be possible, but as a rule the monosubstituted Ar radicals are preferred.
- Ar can also be a substituted heteroaromatic, such as preferably pyridine or pyrazine. But Ar can also be used for a political aromatic hydrocarbon, such as.
- naphthalene, anthracene, or quinoline stand in enantiomeric cyanoethanol ester 2-cyanoethyl (4S) -4- (4-cyano-2-methoxyphenyl) -5-ethoxy-2,8-dimethyl-1,4- dihydro-1,6-naphthyridine-3-carboxylate of the formula (I IVa)
- Ar for one of the formulas stands where * stands for the linkage point.
- Particularly preferred is a process for the preparation of (4S) -4- (4-cyano-2-methoxyphenyl) -5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carbox- amide of formula (Ia), where in formula (III) Ar is one of the formulas stands where * stands for the linkage point.
- a process for the preparation of (4S) -4- (4-cyano-2-methoxyphenyl) -5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carbox is very particularly preferred -amid of the formula (Ia), characterized in that one racemic cyanoethanol ester of the formula (IV) with a chiral substituted tartaric acid ester of the formula (IIIa)
- Diastereomer salt according to paragraph 12 characterized in that Ar is for stands where * stands for the point of attachment. 14. Diastereomer salt according to paragraph 12 or 13, characterized in that Ar is for stands where * stands for the point of attachment.
- Ar is selected for a heteroaryl group from the group consisting of thienyl, furanyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thirazadiazolyl or; or a 6-membered heteroaryl group such as pyridinyl, pyridazinyl,
- R1, R2, R3, R4, R5 each represent a hydrogen atom or an alkyl radical, such as, for example, methyl, ethyl, propyl or a halogen atom, such as, for example, fluorine, chlorine, bromine or iodine or an ether group, such as, for example, O-methyl, O-ethyl, O-phenyl, or a nitro group, or a cyano group, or a CF3 group, or an amide group, such as, for example, -NHCOR, in which R is methyl, ethyl or Phenyl, or -NRCOR in which R has the meaning given above or CONHR-in which R has the meaning given above or CONRR ', in which R' is synonymous with R as defined above or for cyclic amides such as 3-oxomorpholine- 4-yl, 2-oxopi
- Ar represents a substituted heteroaromatic, such as preferably pyridine or pyrazine; or
- Ar is a polycyclic aromatic hydrocarbon such as a substituted naphthalene, anthracene, or quinoline.
- step (10) Process according to paragraph (8) or (9), the racemate resolution in step (i) taking place in an organic solvent or in solvent mixtures which consist of water and water-miscible organic solvents.
- the mixed solvent is selected from ethyl acetate / methanol 90:10; Methanol / water 80:20; Ethanol / water 90:10; Ethanol / water 85:15; Ethanol / water 80:20; Ethanol / water 75:25; Ethanol / water 70:30; Dichloromethane; 1-propanol / water 80:20; 1-pentanol; 1-pentanol / water 90:10; Isopropanol; Isopropanol / water 80:20; Isobutanol / water 90:10; Isobutanol / water 80:20; Cyclohexanol / water 90:10; Benzyl alcohol / water 90:10; Ethylene glycol; and ethylene glycol / water 80:20, the mixing ratios being given in volume per volume (vol / vol).
- step (i) Process according to one of paragraphs (8) to (16), the resolution in step (i) being carried out in an ethanol / water mixture.
- step (i) Process according to one of paragraphs (8) to (17), the racemate resolution in step (i) taking place at a temperature in the range from 20 ° C to 50 ° C.
- step (i) Process according to one of paragraphs (8) to (18), wherein the racemate resolution in step (i) takes place at a temperature of 30 ° C to 50 ° C.
- step (ii) Isolating the precipitated diastereomer salt (Va), (Vb), (Vc) and / or (Vd), step (ii) taking place after step (i).
- (22) Process according to one of paragraphs (8) to (21) for the preparation of the diastereomer salt (Va) and / or
- step (i) where in step (i) the chiral substituted tartaric acid ester of the formula (IIIa) is used and where Ar is defined as in one of paragraphs (1), (2), (3), (4), (5), (6) or (7).
- step (i) 0.5 to 2.0 equivalents of the tartaric acid ester (IIIa) or (IIIb) are used for the resolution of the racemate.
- step (i) 0.7 to 1.5 equivalents of the tartaric acid ester (IIIa) or (IIIb) are used for the resolution of the racemate.
- step (i) 0.7 to 1.4 equivalents of the tartaric acid ester (IIIa) or (IIIb) are used for the resolution of the racemate.
- step (iii) converting the diastereomer salt obtained in step (i) to the compound of the formula (IVa).
- Ar is defined according to one of paragraphs (2) to (7).
- step (i) being defined according to one of paragraphs (8) to (27).
- step (ii) isolating the precipitated diastereomer salt (Va), (Vb), (Vc) and / or (Vd), wherein step (ii) optionally takes place after step (i) and before step (iii).
- step (ii) being defined according to one of paragraphs (21) to (27).
- step (iii) Treating the diastereomer salt (Va), (Vb), (Vc) and / or (Vd) obtained in step (i) with a base.
- step (iii) the base is an organic or inorganic base.
- step (iii) the base is an inorganic base and is selected from ammonia, sodium hydroxide solution, lithium hydroxide, potassium hydroxide, ammonium carbonate, sodium carbonate, potassium carbonate, lithium carbonate, ammonium hydrogen carbonate, Sodium hydrogen carbonate, potassium hydrogen carbonate, sodium phosphate, potassium phosphate, ammonium phosphate, sodium hydroxide and mixtures thereof.
- step (iii) the base is an organic base and is selected from aliphatic and aromatic bases.
- step (iii) the base is an organic base and is selected from triethylamine, imidazole, N-methylimidazole, Hünig base, pyridine, DBU and their mixtures.
- n step (iii) the base is selected from potassium hydroxide, potassium phosphate, sodium phosphate and mixtures thereof.
- Solvent is selected from water, water-miscible organic solvents, ethanol, isopropanol, 1,2-ethanediol, methoxyethanol, methanol, acetone, brandy and mixtures thereof. (41) Method according to one of the paragraphs Method according to one of the paragraphs (28) to (40), whereby the
- Solvent is selected from mixtures of water and ethanol, the mixing ratio (vol / vol) in the range of ethanol: water being 1: 6 to 1: 3.
- step (iv) removing the solvent, step (iv) optionally taking place after step (iii).
- (48) Process according to one of paragraphs (28) to (47), wherein the racemate (IV) in step (i) with (+) di-p-tolyl-D-tartaric acid of the formula (IIIa ') in a brandy / water mixture to the diastereomer salt (Va) is implemented, and then in step (iii) cyanoethanol ester (IVa) is also released in a liquor / water mixture using sodium phosphate.
- (49) Process for the preparation Process for the preparation of (4S) -4- (4-Cyano-2-methoxyphenyl) -5-ethoxy-
- 2,8-dimethyl-1,4-dihydro-1,6-naphthyridin-3-carbox-amide of the formula (Ia), comprise steps (i), (iii), (v), and (vi)
- step (iii) converting the diastereomer salt obtained in step (i) to the compound of the formula (IVa).
- step (i) is defined according to one of paragraphs (8) to (48).
- step (iii) being defined according to one of paragraphs (28) to (48).
- Table 3 below shows the structures of the compounds found in the HPLC. The assignment of the retention times in HPLC is given below.
- Ultra high-performance liquid chromatograph (with a pressure range of up to 1200 bar with thermostated column oven and UV detector
- Length 100 mm, inner diameter: 3.0 mm, particle size: 1.9 ⁇ m, maximum pressure: 1000 bar
- Length 250 mm, inner diameter: 4.6 mm, particle size: 5.0 ⁇ m, maximum pressure: 300 bar
- Device / detector high-performance liquid chromatograph with thermostated column oven, UV detector and data analysis system Measuring wavelength: 252 nm Oven temperature: 40 ° C
- Test solution approx. 0.5 mg / mL of the substance racemate, dissolve with sample solvent.
- Reference solution A reference solution is prepared analogous to the test solution
- Solution A 0.58 g ammonium hydrogen phosphate and 0.66 g ammonium dihydrogen phosphate in 1 L water (ammonium phosphate buffer pH 7.2)
- Solution B acetonitrile 0 min: 30% B; 70% A 15 min: 80% B; 20% A 25 min: 80% B; 20% A.
- Device / detector high-performance liquid chromatograph with thermostated column oven, UV detector and data evaluation system
- Enantiomeric purity (e.e%): 98% e.e.
- a sodium hydroxide solution (prepared from 82 g of 45% aqueous sodium hydroxide (924.8 mmol) and 423 ml of water) was added dropwise to this solution at 0 ° C. over the course of 15 minutes, and the mixture was subsequently stirred at 0 ° C. for 1.5 hours. It was extracted twice with 480 ml of methyl tert-butyl ether each time and once with 480 ml of ethyl acetate. The aqueous solution was adjusted to pH 7 at 0 ° C. with dilute hydrochloric acid (prepared from 37.1 g of 37% HCl and 151 ml of water). The mixture was allowed to warm to 20 ° C.
- Modification Mod A (as defined in WO2016 / 016287 A1)
- Enantiomeric purity (e.e%): 79% e.e.
- Enantiomeric purity (e.e%): 99% e.e.
- Modification Mod A (as defined in WO2016 / 016287 A1).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19203825 | 2019-10-17 | ||
PCT/EP2020/078613 WO2021074078A1 (de) | 2019-10-17 | 2020-10-12 | Verfahren zur herstellung von 2-cyanoethyl (4s)-4-(4-cyano-2-methoxy-phenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxylat durch racemat-spaltung mittels diastereomerer weinsäureester |
Publications (1)
Publication Number | Publication Date |
---|---|
EP4045501A1 true EP4045501A1 (de) | 2022-08-24 |
Family
ID=68281313
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20789971.7A Pending EP4045501A1 (de) | 2019-10-17 | 2020-10-12 | Verfahren zur herstellung von 2-cyanoethyl (4s)-4-(4-cyano-2-methoxy-phenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxylat durch racemat-spaltung mittels diastereomerer weinsäureester |
Country Status (15)
Country | Link |
---|---|
US (1) | US20240199599A1 (de) |
EP (1) | EP4045501A1 (de) |
JP (1) | JP2022553230A (de) |
KR (1) | KR20220084103A (de) |
CN (1) | CN114698375A (de) |
AU (1) | AU2020367978A1 (de) |
BR (1) | BR112022005511A2 (de) |
CA (1) | CA3158166A1 (de) |
CO (1) | CO2022004446A2 (de) |
CR (1) | CR20220157A (de) |
IL (1) | IL292180A (de) |
JO (1) | JOP20220089A1 (de) |
MX (1) | MX2022004467A (de) |
PE (1) | PE20221322A1 (de) |
WO (1) | WO2021074078A1 (de) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115340539B (zh) * | 2022-01-19 | 2024-02-27 | 奥锐特药业股份有限公司 | 制备非奈利酮及其中间体的方法 |
CN115340540A (zh) * | 2022-01-20 | 2022-11-15 | 奥锐特药业股份有限公司 | 制备非奈利酮及其中间体的方法 |
WO2023205164A1 (en) | 2022-04-18 | 2023-10-26 | Teva Pharmaceuticals International Gmbh | Processes for the preparation of finerenone |
WO2023223188A1 (en) * | 2022-05-16 | 2023-11-23 | Glenmark Life Sciences Limited | Process for the preparation of finerenone and intermediates thereof |
CN115322194B (zh) * | 2022-08-23 | 2024-04-09 | 浙江国邦药业有限公司 | 一种非奈利酮中间体羧酸拆分方法 |
WO2024094181A1 (zh) * | 2022-11-04 | 2024-05-10 | 南京威凯尔生物医药科技有限公司 | 通过非对映酒石酸酯拆分外消旋体制备非奈利酮的方法 |
CN116715664A (zh) * | 2023-06-12 | 2023-09-08 | 常州制药厂有限公司 | 一种非奈利酮关键中间体的制备方法 |
CN118026867A (zh) * | 2024-04-12 | 2024-05-14 | 南京道尔医药研究院有限公司 | 一种制备2-(1r,5s,6s)-6-(氨甲基)-3-乙基双环[3.2.0]庚烷-3-烯-6-乙酸的方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995031436A1 (en) * | 1994-05-16 | 1995-11-23 | Merrell Pharmaceuticals Inc. | PROCESS AND DIASTEREOMERIC SALTS USEFUL FOR THE OPTICAL RESOLUTION OF RACEMIC α-[4-(1,1-DIMETHYLETHYL)PHENYL]-4-(HYDROXYDIPHENYLMETHYL)-1-PIPERIDINEBUTANOL AND DERIVATIVE COMPOUNDS |
US20050026886A1 (en) * | 2003-07-29 | 2005-02-03 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor |
HUE029336T2 (en) * | 2005-09-16 | 2017-02-28 | Daiichi Sankyo Co Ltd | For the preparation of an optically active diamine derivative and process |
DE102007009494A1 (de) * | 2007-02-27 | 2008-08-28 | Bayer Healthcare Ag | Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung |
PL3174875T3 (pl) * | 2014-08-01 | 2021-01-25 | Bayer Pharma Aktiengesellschaft | Sposób wytwarzania (4S)-4-(4-cyjano-2-metoksyfenylo)-5-etoksy-2,8-dimetylo-1,4-dihydro-1,6-naftyrydyno-3-karboksyamidu i jego oczyszczanie do zastosowania jako aktywny składnik farmaceutyczny |
RU2715226C2 (ru) * | 2015-08-21 | 2020-02-26 | Байер Фарма Акциенгезельшафт | Способ получения (4s)-4-(4-циано-2-метоксифенил)-5-этокси-2,8-диметил-1,4-дигидро-1,6-нафтиридин-3-карбоксамида и выделения (4s)-4-(4-циано-2-метоксифенил)-5-этокси-2,8-диметил-1,4-дигидро-1,6-нафтиридин-3-карбоксамида посредством электрохимических методов |
-
2020
- 2020-10-12 IL IL292180A patent/IL292180A/en unknown
- 2020-10-12 MX MX2022004467A patent/MX2022004467A/es unknown
- 2020-10-12 CN CN202080072478.9A patent/CN114698375A/zh active Pending
- 2020-10-12 EP EP20789971.7A patent/EP4045501A1/de active Pending
- 2020-10-12 KR KR1020227015998A patent/KR20220084103A/ko unknown
- 2020-10-12 BR BR112022005511A patent/BR112022005511A2/pt not_active Application Discontinuation
- 2020-10-12 AU AU2020367978A patent/AU2020367978A1/en active Pending
- 2020-10-12 US US17/769,263 patent/US20240199599A1/en active Pending
- 2020-10-12 PE PE2022000583A patent/PE20221322A1/es unknown
- 2020-10-12 CA CA3158166A patent/CA3158166A1/en active Pending
- 2020-10-12 JO JOP/2022/0089A patent/JOP20220089A1/ar unknown
- 2020-10-12 CR CR20220157A patent/CR20220157A/es unknown
- 2020-10-12 WO PCT/EP2020/078613 patent/WO2021074078A1/de active Application Filing
- 2020-10-12 JP JP2022522993A patent/JP2022553230A/ja active Pending
-
2022
- 2022-04-07 CO CONC2022/0004446A patent/CO2022004446A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP2022553230A (ja) | 2022-12-22 |
WO2021074078A1 (de) | 2021-04-22 |
CR20220157A (es) | 2022-06-02 |
BR112022005511A2 (pt) | 2022-06-21 |
MX2022004467A (es) | 2022-05-03 |
CO2022004446A2 (es) | 2022-04-29 |
KR20220084103A (ko) | 2022-06-21 |
AU2020367978A1 (en) | 2022-05-12 |
JOP20220089A1 (ar) | 2023-01-30 |
PE20221322A1 (es) | 2022-09-09 |
US20240199599A1 (en) | 2024-06-20 |
CN114698375A (zh) | 2022-07-01 |
CA3158166A1 (en) | 2021-04-22 |
IL292180A (en) | 2022-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP4045501A1 (de) | Verfahren zur herstellung von 2-cyanoethyl (4s)-4-(4-cyano-2-methoxy-phenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxylat durch racemat-spaltung mittels diastereomerer weinsäureester | |
EP3784668A1 (de) | Verfahren zur herstellung (4s)- 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4- dihydro-1,6-naphthyridin-3-carbox-amid durch racemat-spaltung mittels diastereomerer weinsäureester | |
EP4045499A1 (de) | Verfahren zur herstellung von 2-cyanoethyl (4s)-4-(4-cyano-2-methoxy-phenyl)-5-hydroxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridin-3-carboxylat durch racemat-spaltung mittels diastereomerer weinsäureester | |
DE60008136T2 (de) | Verbessertes verfahren zur herstellung von n-substituierte aminotetraline | |
DE4427079C2 (de) | Verfahren zur Racemisierung von Enantiomeren der alpha-Liponsäure | |
EP0546388A1 (de) | Azaheterocyclylmethyl-chromane als Wirkstoffe zur Behandlung von Erkrankungen des Zentralnervensystems | |
DE102005027517A1 (de) | Verfahren zur Herstellung von Dihydrochinazolinen | |
EP4045502A1 (de) | Photochemisches verfahren zur herstellung von (4r, 4s)- 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridin-3-carbox-amid | |
WO2021074077A1 (de) | Verfahren zur herstellung von acyloxymethylestern der (4s) -(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridin-3-carbonsäure | |
EP3271337B1 (de) | Verfahren zur herstellung von (4s)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluormethyl)phenyl]-1,2,3,4-tetrahydro pyrimidin-5-carbonitril | |
DE60110043T2 (de) | Methode zur synthetisierung von leflunomid | |
CN102351847A (zh) | 一种工业化的埃索美拉唑钠盐的精制方法 | |
WO1996005837A1 (de) | Verwendung von n-substituierten phenothiazinen | |
CH639639A5 (en) | Alpha-fluoromethyl-alpha-amino-alkanoic acids and their esters | |
EP0539803A1 (de) | Triazaspirodecanon-Methyl-Chromane zur Bekämpfung von Erkrankungen des Zentralnervensystems | |
DE2138122C3 (de) | Verfahren zur Gewinnung von D-Penicillamin | |
DE2362687C3 (de) | Verfahren zur Gewinnung der optischen Isomeren des Penicillamins | |
DE69030774T2 (de) | Optisch aktive Diastereoisomersalze von Tetrahydro-2-furancarbonsäure | |
DE112020001032T5 (de) | Verfahren zur Herstellung von Levoamphetamin | |
EP0595166B1 (de) | 4-Heterocyclyl substituierte Dihydropyridine | |
EP0483063B1 (de) | Ergolinderivate | |
EP1737868B1 (de) | Stereoselektives verfahren zur herstellung von clopidogrel | |
CN115108977A (zh) | 一种瑞戈非尼的制备方法 | |
CN112898234A (zh) | 一种盐酸兰地洛尔中间体的制备方法 | |
DE3304361A1 (de) | Mutterkornalkaloide, verfahren zu deren herstellung sowie diese verbindungen enthaltende pharmazeutische zusammensetzungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20220517 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
RAX | Requested extension states of the european patent have changed |
Extension state: BA Payment date: 20220517 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20230817 |